Literature DB >> 34924560

Correction: AHR mediates the Aflatoxin B1 toxicity associated with hepatocellular carcinoma.

Qing Zhu1, Yarui Ma1, Junbo Liang2, Zhewen Wei3, Mo Li1, Ying Zhang1, Mei Liu1, Huan He1, Chunfeng Qu1, Jianqiang Cai3, Xiaobing Wang4,5, Yixin Zeng6,7, Yuchen Jiao8,9,10.   

Abstract

Entities:  

Year:  2021        PMID： 34924560      PMCID： PMC8685275          DOI： 10.1038/s41392-021-00794-y

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN： 2059-3635


× No keyword cloud information.
Correction to: Signal Transduction and Targeted Therapy 10.1038/s41392-021-00713-1, published online 9 August 2021 After online publication of the article[1], the authors noticed one inadvertent mistake occurred during the production process in Fig. 7 that needs to be corrected. The correct data are provided as follows. The key findings of the article are not affected by these corrections. The original article has been corrected.
Fig. 7

e Flow cytometry assessing the proportion of CD4/8+ cells with fluorescent antibodies against the cell markers indicated.

e Flow cytometry assessing the proportion of CD4/8+ cells with fluorescent antibodies against the cell markers indicated.
  1 in total

1.  AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma.

Authors:  Qing Zhu; Yarui Ma; Junbo Liang; Zhewen Wei; Mo Li; Ying Zhang; Mei Liu; Huan He; Chunfeng Qu; Jianqiang Cai; Xiaobing Wang; Yixin Zeng; Yuchen Jiao
Journal:  Signal Transduct Target Ther       Date:  2021-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.